Integrated Mathematical Oncology Faculty

Alexander AndersonAlexander RA Anderson, PhD - Senior Member

The Anderson Lab is focused on integrating mathematical and computational modeling approaches with experimental and clinical data to better understand cancer growth and development and translate this understanding into novel therapies.

Lab website


Noemi Andor, PhD - Assistant Member

Noemi AndorWe develop and integrate algorithms to quantify the clonal composition of a tumor from different perspectives, including its genome, transcriptome or morphology. The goal is using these clone characteristics to inform how a tumor’s environment can be altered to favor certain tumor subclones over others. A first instance of this translates into testing the potential of a clone’s genomic instability as biomarker of its sensitivity to DNA damaging drugs.

Lab website


David Basanta

David Basanta Gutierrez, PhD - Associate Member

To understand the evolutionary dynamics of cancer using integrative approaches so that one day we will be able to exert some control on cancer progression. My work will focus on mathematical and computational models of cancer evolution.

 


Joel BrownJoel Brown, PhD - Senior Member

We apply theoretical evolutionary biology models, together with computational, bioinformatics and statistical approaches to cancer cell biology. I use a combination of mathematical and experimental approaches to understand how organisms interact with and shape their environments.

 


Heiko EnderlingHeiko Enderling, PhD – Associate Member

Dr. Enderling's research interests are focused on developing clinically and experimentally motivated and quantitative models of cell-cell interactions within a tumor as well as at the tumor-host interface. In particular, the work in his laboratory focuses on the role of cancer stem cells in tumor progression and treatment response, with the ultimate goal to improve patient-specific treatment design.

Lab website


Kasia RejniakKasia Rejniak, PhD - Associate Member

My lab's research is focused on understanding how the heterogeneous and dynamically changing tumor microenvironment can be harnessed to design more effective treatment protocols. In close collaboration with experimentalists and clinicians, we develop mathematical models of in silico organoids and micro-pharmacology based on tumor-specific histology and quantitative image analyses to predict tumor response to combined (chemo-, immuno- and targeted) therapies and to optimize their schedules. 

Lab website


Ariosto S. Silva, PhD - Associate Member, Cancer Physiology

Ariosto SilvaDuring my research career, I have focused on how to improve the survival of cancer patients through optimization of therapy. Through a long-term collaboration with the Moffitt Myeloma Working Group (MMWG), I have developed a combination of ex vivo chemosensitivity assay and computational model of therapy response, capable of extrapolating six days of experimental data into months of clinical response using fresh bone marrow samples from standard-of-care biopsies. As such, we have created patient/drug-specific mathematical models that, when parameterized by drug-specific pharmacokinetics and dosing schedule, yield predictions of clinical response. In addition, we have developed a systems biology pipeline to integrate these findings with multi-omics molecular data to infer mechanisms driving disease progression and the emergence of drug resistance.

Lab website


Jeffrey WestJeffrey West, PhD - Assistant Member, Integrated Mathematical Oncology

The goal of my research group is to aid in targeting treatment resistance by constructing mathematical models of 1) tumor evolution and heterogeneity and 2) evolutionary-minded treatment strategies, employing techniques such as agent-based modeling, dose-response convexity analysis (second-order effects), and evolutionary game theory. These methods are broadly applicable to many cancer types, but recent publications have focused on applications to breast and prostate cancer.

Lab website